Your First Month on Mounjaro: A Week-by-Week Picture

The first month runs entirely on the 2.5 mg dose — the starter level designed to let your body adjust, not to deliver peak results.
Appetite changes are commonly the first signal: earlier fullness, reduced cravings, less interest in large portions, often noticed before the scales move.
Side effects, when they occur, are typically gastrointestinal (nausea, loose stools, indigestion) and tend to ease as the weeks progress.
Weight loss in month 1 varies considerably between individuals; the clinical trials measured results over 72 weeks, not four.

Most people who complete one month on Mounjaro describe the same arc: an unsettled first fortnight, then a settling. By week four, appetite has usually shifted noticeably — earlier fullness, less interest in snacking, food taking up less mental space than it did before. Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist, and the opening four weeks are almost always spent at the 2.5 mg starter dose, which is calibrated for tolerance rather than maximum effect. It is a prescription-only medicine; a GPhC-registered prescriber assesses whether it is clinically appropriate before any treatment begins.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

What actually happens, week by week, during month 1 on Mounjaro

Step 1, Your first injection (week one): adjustment begins

The first pen contains four weekly doses of 2.5 mg. Many people feel little on day one. By days three to five, the medicine's effects on gastric emptying begin to register: food moves through the stomach more slowly, and fullness arrives sooner. For some people that shift is subtle; for others it is quite pronounced.

Nausea is the side effect reported most often in week one. It rarely arrives with any warning and can feel worse in the hour after eating a rich or fatty meal. Keeping portions moderate, eating slowly and staying well hydrated all help. The foods that sit most comfortably on Mounjaro tend to be plain, lower-fat options, something many people work out through trial and error in these early days.

Injection-site reactions (mild redness, itching) can occur. Rotating between the abdomen, thigh and upper arm, and allowing the pen to reach room temperature before use, reduces them. Your Patient Information Leaflet covers every detail of correct injection technique; follow it alongside any guidance from your prescriber.

Step 2, Weeks two and three: the appetite shift becomes real

This is typically when people notice the change most clearly. Portion sizes that felt normal a fortnight ago now feel too large. The urge to eat between meals quietens. Some people describe a reduced interest in foods they previously found hard to resist.

Weight loss, if it appears, is often modest at this stage, not because the medicine is not working, but because 2.5 mg is the settling-in dose. The SURMOUNT-1 trial, published in the New England Journal of Medicine, measured its results over 72 weeks across thousands of participants; month one is the foundation of that longer journey. Comparing your four-week result to someone else's or to the trial's headline figures misses how the medicine is designed to work.

GI side effects often ease noticeably by week three, though they do not disappear entirely for everyone at this stage. Constipation replaces nausea as the more common complaint for some people; fibre, fluids and gentle movement help. If diarrhoea or vomiting is severe and persistent, contact your prescriber, serious dehydration can follow.

Step 3, Week four: reviewing where you are before the next decision

Week four is the natural pause point. Your first pen is complete and a prescriber reviews whether to continue at 2.5 mg or move to 5 mg. At nume, every repeat order receives a fresh clinical review before dispatch, a named prescriber reads your update, not automated software.

Most people do move to 5 mg at this point, but clinical review sometimes recommends staying at 2.5 mg if side effects are still noticeable. That is not a setback; it is the titration schedule working exactly as intended. The NHS tirzepatide page explains why gradual dose increases are built into the treatment plan.

If you are curious about what tends to happen next, month two on Mounjaro typically brings the first therapeutic dose and, for many people, more visible progress on the scales. Many people also find it useful to read about what the first month on Mounjaro is actually like to set realistic expectations before they begin.

On the cost side, understanding how Mounjaro is priced across UK providers is worth doing before you start, so that the ongoing expense does not come as a surprise. Current pricing at nume is shown on the treatment page, alongside everything that is included in the one transparent price.

When to contact a clinician during month 1

Most people move through their first four weeks without anything that requires urgent attention. A few situations do warrant a call or message to your prescriber rather than waiting. Severe, persistent stomach pain that extends to your back (with or without vomiting) should be assessed promptly; the MHRA's Drug Safety Update guidance on GLP-1 medicines identifies acute pancreatitis as an infrequent but serious risk. Signs of an allergic reaction (swelling, difficulty breathing, widespread rash) need emergency care. Significant dehydration from ongoing vomiting or diarrhoea, sudden changes in vision, or thoughts of self-harm are all reasons to seek help without delay.

Anything less urgent (questions about missed doses, what to eat, whether a symptom is normal) belongs with your prescriber or the aftercare team. At nume, that support runs seven days a week. The FAQs page covers common first-month questions, and if you want a clearer picture of the results and side effects people typically report at the four-week mark, what Mounjaro is like after 1 month is a useful read before you contact the team. The contact page connects you directly with the team. If you have not yet started and want to discuss whether tirzepatide is suitable for you, speaking to our prescribers through a free consultation is the place to begin.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions